维普中文期刊产品整合服务
11篇 您的检索式:作者名="Volfova"
    题名 作者 年代 出处 被引量
1Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection显示文摘AIM: To identify predictors of sustained virological response in hemodialysed patients treated by PEGinterferon α for chronic hepatitis C, genotype 1.METHODS: The sustained virological response(SVR) rate, IL28 B genotype, IFNL4 genotype, initial viral load(IVL) and other pretreatment variables in 39 endstage renal disease patients(ESRD) on maintenance haemodialysis(HD) infected with hepatitis C virus(HCV), genotype 1b, were compared with a control group of 109 patients with normal kidney function treated within the same period. All the patients were treatment nave and had well compensated liver disease. The ESRD patients received 135 μg of PEGylated interferon α-2a(Peg IFN-α) weekly and a reduced dose of ribavirin(RBV) was administered to 23/39 patients with an initial haemoglobin level > 10 g/d L. Control group patients were given standard doses of Peg IFN-α and RBV. SVR was assessed as HCV RNA negativity 24 wk post-treatment. A t-test or ANOVA were used for comparisons of the means and a χ2 testcompared the frequencies.Logistic regression was used to determine significant predictors of SVR.Cutoff values for continuous variables were obtained from Receiver Operating Characteristic analysis.RESULTS:The distribution of IL28B rs12979860 CC,CT and TT genotypes in the ESRD group was 28.2%,64.1%and 7.7%,respectively,and 19.3%,62.4%and18.3%in the controls.The IFNL4 genotype was in almost absolute linkage disequlibrium with IL28B.The proportion of patients with a low IVL(<600000 IU/m L)was significantly higher in the ESRD group than in the controls(28/39,71.8%vs 51/109,46.8%,P=0.009),as was the proportion of patients with low IVL in IL28B CC carriers compared with non-CC carriers in the ESRD group(10/11,90.9%vs 18/28,64.3%,P=0.0035).This difference was not found in the controls(7/22,31.8%vs 44/87,50.6%,P=0.9).The overall SVR rate was 64.1%(25/39)in the ESRD group and 50.5%(55/109)in the control group(P=0.19).11/11(100%)and 19/22(86.4%)IL28B CC patients achieved SVR in the ESRD and control groups,respectively.A statistically significant association between SVR and IL28B and IFNL4 variants was found in both groups.The ESRD patients who achieved SVR showed the lowest IVL[median 21000,interquartile range(IQR):6000-23000IU/m L],compared with ESRD individuals without SVR(1680000,IQR:481000-6880000,P=0.001),controls with SVR(387000,IQR:111000-1253000)and controls without SVR(905000,IQR:451000-3020000).In ESRD,an IVL<600000 IU/m L was strongly associated with SVR:24/28(85.7%)patients who achieved SVR had viraemia below this threshold.CONCLUSION:Haemodialysis decreases the viral load,especially in IL28B CC genotype carriers.A low IVL was the strongest predictor of SVR in ESRD patients identified in multivariate analysis.Jan Sperl Sona Frankova Renata Senkerikova Magdalena Neroldova Vaclav Hejda Miroslava Volfova Dusan Merta Ondrej Viklicky Julius Spicak Milan Jirsa 2015World Journal of Gastroenterology2015,21,18:2
2Propenies of polystyrene/poly (butyl acrylate) core/shell polyrners modified with N - methylol acrylamide显示文摘VOLFOVA P CttRASTOVA V CERNAKOVA L el al 2001Maeromolecular Symposia2001,170,1:1
3Properties of polystyrene/poly(butyl acrylate) core/shell polymers modified withN-methylol acrylamide 显示文摘Volfova P Chrastova V Cernakova L 2011Macromol Symp2011,170,1:1
4Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial显示文摘Stephan R. Targan Brian G. Feagan Richard N. Fedorak Bret A. Lashner Remo Panaccione Daniel H. Present Martina E. Spehlmann Paul J. Rutgeerts Zsolt Tulassay Miroslava Volfova Douglas C. Wolf Chito Hernandez Jeffrey Bornstein William J. Sandborn 2007Gastroenterology2007,,:1
5Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial显示文摘Stephan R. Targan Brian G. Feagan Richard N. Fedorak Bret A. Lashner Remo Panaccione Daniel H. Present Martina E. Spehlmann Paul J. Rutgeerts Zsolt Tulassay Miroslava Volfova Douglas C. Wolf Chito Hernandez Jeffrey Bornstein William J. Sandborn 2007Gastroenterology2007,,5:1
6A phase 2 dose ranging,double-blind,placebo-controlled study of Alicaforsen enema in subjects with acute exacerbation of mild to moderate leftsided ulcerative colitis显示文摘VAN DEVENTER SJ VOLFOVA M FLISIAK R 2005Gastroenterology2005,128,:1
7Cystic polyposis of the stomach (fundic gland polyps)-relationship to the absence of Helicobacter pylori infection and a therapy with drugs suppressing gastric acidity 显示文摘Fixa B Vanatsek T Volfova M 2012Cas Lek Cesk2012,151,4:1
8Cystic polyposis of the stomach (fundic gland polyps)--relationship to the absence of Helicobacter pylorl infection and a therapy with drugs suppressing gastric acidity 显示文摘Fixa B Vanasek T Volfova M 2012Cas Lek Cesk2012,151,4:1
9Formation and location of ceUulases in a cellulomonas culture on bagasse 显示文摘Rodriguez H Volfova O 1984Appl Microbiol Biotechnol1984,19,:1
10Monitoring of Epstein-Barr virus load in patients after allogeneic hematopoietic stem cell transplantation显示文摘Volfova P Lengerova M Winterova J 2012Infection2012,40,:1
11Formation and location of cellulases in a cellulomonas culture on bagasse显示文摘Rodriguez H Volfova O 1984Applied Microbiology and Biotechnology1984,19,:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费